{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:45:55Z","timestamp":1780616755228,"version":"3.54.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Japanese Ministry of Health, Labour and Welfare"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate the potential contribution of accessory respiratory muscle atrophy to the decline of forced vital capacity (FVC) in patients with SSc-associated interstitial lung disease (ILD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This single-centre, retrospective study enrolled 36 patients with SSc-ILD who underwent serial pulmonary function tests and chest high-resolution CT (HRCT) simultaneously at an interval of 1\u20133\u2009years. The total extent of ILD and chest wall muscle area at the level of the ninth thoracic vertebra on CT images were evaluated by two independent evaluators blinded to the patient information. Changes in the FVC, ILD extent, and chest wall muscle area between the two measurements were assessed in terms of their correlations. Multiple regression analysis was conducted to identify the independent contributors to FVC decline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Interval changes in FVC and total ILD extent were variable among patients, whereas chest wall muscle area decreased significantly with time (P=0.0008). The FVC change was negatively correlated with the change in ILD extent (r=\u22120.48, P=0.003) and was positively correlated with the change in the chest wall muscle area (r\u2009=\u20090.53, P=0.001). Multivariate analysis revealed that changes in total ILD extent and chest wall muscle area were independent contributors to FVC decline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients with SSc-ILD, FVC decline is attributable not only to the progression of ILD but also to the atrophy of accessory respiratory muscles. Our findings call attention to the interpretation of FVC changes in patients with SSc-ILD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa322","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T11:36:07Z","timestamp":1589456167000},"page":"250-255","source":"Crossref","is-referenced-by-count":19,"title":["Chest wall muscle atrophy as a contributory factor for forced vital capacity decline in systemic sclerosis-associated interstitial lung disease"],"prefix":"10.1093","volume":"60","author":[{"given":"Takashi","family":"Nawata","sequence":"first","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo"},{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Shirai","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikito","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-6136","authenticated-orcid":false,"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"2021010517013854400_keaa322-B1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J\u00a0Scleroderma Relat Disord"},{"key":"2021010517013854400_keaa322-B2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/2397198319889549","article-title":"Natural history of systemic sclerosis-related interstitial lung disease: how to identify a progressive fibrosing phenotype","volume":"5","author":"Volkmann","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"2021010517013854400_keaa322-B3","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3899\/jrheum.160339","article-title":"Elevated serum Krebs von den Lungen-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease","volume":"43","author":"Kuwana","year":"2016","journal-title":"J Rheumatol"},{"key":"2021010517013854400_keaa322-B4","doi-asserted-by":"crossref","first-page":"E71","DOI":"10.1016\/S2665-9913(19)30144-4","article-title":"The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements","volume":"2","author":"Hoffman-Void","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2021010517013854400_keaa322-B5","doi-asserted-by":"crossref","first-page":"170102.","DOI":"10.1183\/16000617.0102-2017","article-title":"Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease","volume":"27","author":"Caron","year":"2018","journal-title":"Eur Respir Rev"},{"key":"2021010517013854400_keaa322-B6","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"2021010517013854400_keaa322-B7","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2021010517013854400_keaa322-B8","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"2021010517013854400_keaa322-B9","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3899\/jrheum.141182","article-title":"Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - report from OMERACT CTD-ILD Working Group","volume":"42","author":"Khanna","year":"2015","journal-title":"J Rheumatol"},{"key":"2021010517013854400_keaa322-B10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.39501","article-title":"The American College of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis","volume":"68","author":"Khanna","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021010517013854400_keaa322-B11","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/rheumatology\/kex196","article-title":"Muscle involvement in systemic sclerosis: points to consider in clinical trial","volume":"56","author":"Walker","year":"2017","journal-title":"Rheumatology"},{"key":"2021010517013854400_keaa322-B12","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s10067-017-3932-y","article-title":"Malnutrition and sarcopenia in a large cohort of patients with systemic sclerosis","volume":"37","author":"Caimmi","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2021010517013854400_keaa322-B13","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021010517013854400_keaa322-B14","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.38953","article-title":"Elevated levels of pentraxin 3 in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis","volume":"67","author":"Shirai","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2021010517013854400_keaa322-B15","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2021010517013854400_keaa322-B16","first-page":"1553","article-title":"Mechanical properties of respiratory muscles","volume":"3","author":"Sieck","year":"2013","journal-title":"Compr Physiol"},{"key":"2021010517013854400_keaa322-B17","doi-asserted-by":"crossref","first-page":"17.","DOI":"10.1186\/s13075-018-1517-z","article-title":"Systemic sclerosis associated interstitial lung disease \u2013 individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group","volume":"20","author":"Adler","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2021010517013854400_keaa322-B18","doi-asserted-by":"crossref","first-page":"17.","DOI":"10.1186\/s40248-019-0179-2","article-title":"Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases","volume":"14","author":"Ciancio","year":"2019","journal-title":"Multidiscip Respir Med"},{"key":"2021010517013854400_keaa322-B19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1759720X16671928","article-title":"Histopathological findings in systemic sclerosis-related myopathy: fibrosis and microangiopathy with lack of cellular inflammation","volume":"9","author":"Corallo","year":"2017","journal-title":"Ther Adv Musculoskelet"},{"key":"2021010517013854400_keaa322-B20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.nut.2018.03.046","article-title":"Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis","volume":"55-56","author":"Siegert","year":"2018","journal-title":"Nutrition"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/1\/250\/35433876\/keaa322.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/1\/250\/35433876\/keaa322.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T08:20:05Z","timestamp":1610266805000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/1\/250\/5875349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,7,23]]},"published-print":{"date-parts":[[2021,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa322","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,7,23]]}}}